Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range0.960 - 10.021 | Open / Close- / - | Float / Outstanding36.568M / 44.074M |
Vol / Avg.2.252K / 998.529K | Mkt Cap94.760M | P/E- | 50d Avg. Price2.030 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float36.568M | EPS-2.400 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.620 | -0.1000 | ||||
REV | 4.270M | 4.024M | -246.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Fortress Biotech (NASDAQ:FBIO), Inozyme Pharma (NASDAQ:INZY), Atossa Therapeutics (NASDAQ:ATOS) and Aligos Therapeutics (NASDAQ:ALGS).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range0.960 - 10.021 | Open / Close- / - | Float / Outstanding36.568M / 44.074M |
Vol / Avg.2.252K / 998.529K | Mkt Cap94.760M | P/E- | 50d Avg. Price2.030 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float36.568M | EPS-2.400 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.620 | -0.1000 | ||||
REV | 4.270M | 4.024M | -246.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Fortress Biotech (NASDAQ:FBIO), Inozyme Pharma (NASDAQ:INZY), Atossa Therapeutics (NASDAQ:ATOS) and Aligos Therapeutics (NASDAQ:ALGS).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range0.960 - 10.021 | Open / Close- / - | Float / Outstanding36.568M / 44.074M |
Vol / Avg.2.252K / 998.529K | Mkt Cap94.760M | P/E- | 50d Avg. Price2.030 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float36.568M | EPS-2.400 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.620 | -0.1000 | ||||
REV | 4.270M | 4.024M | -246.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Fortress Biotech (NASDAQ:FBIO), Inozyme Pharma (NASDAQ:INZY), Atossa Therapeutics (NASDAQ:ATOS) and Aligos Therapeutics (NASDAQ:ALGS).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range0.960 - 10.021 | Open / Close- / - | Float / Outstanding36.568M / 44.074M |
Vol / Avg.2.252K / 998.529K | Mkt Cap94.760M | P/E- | 50d Avg. Price2.030 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float36.568M | EPS-2.400 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.620 | -0.1000 | ||||
REV | 4.270M | 4.024M | -246.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Fortress Biotech (NASDAQ:FBIO), Inozyme Pharma (NASDAQ:INZY), Atossa Therapeutics (NASDAQ:ATOS) and Aligos Therapeutics (NASDAQ:ALGS).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range0.960 - 10.021 | Open / Close- / - | Float / Outstanding36.568M / 44.074M |
Vol / Avg.2.252K / 998.529K | Mkt Cap94.760M | P/E- | 50d Avg. Price2.030 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float36.568M | EPS-2.400 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.620 | -0.1000 | ||||
REV | 4.270M | 4.024M | -246.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Fortress Biotech (NASDAQ:FBIO), Inozyme Pharma (NASDAQ:INZY), Atossa Therapeutics (NASDAQ:ATOS) and Aligos Therapeutics (NASDAQ:ALGS).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range0.960 - 10.021 | Open / Close- / - | Float / Outstanding36.568M / 44.074M |
Vol / Avg.2.252K / 998.529K | Mkt Cap94.760M | P/E- | 50d Avg. Price2.030 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float36.568M | EPS-2.400 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.620 | -0.1000 | ||||
REV | 4.270M | 4.024M | -246.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Fortress Biotech (NASDAQ:FBIO), Inozyme Pharma (NASDAQ:INZY), Atossa Therapeutics (NASDAQ:ATOS) and Aligos Therapeutics (NASDAQ:ALGS).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range0.960 - 10.021 | Open / Close- / - | Float / Outstanding36.568M / 44.074M |
Vol / Avg.2.252K / 998.529K | Mkt Cap94.760M | P/E- | 50d Avg. Price2.030 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float36.568M | EPS-2.400 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.620 | -0.1000 | ||||
REV | 4.270M | 4.024M | -246.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Fortress Biotech (NASDAQ:FBIO), Inozyme Pharma (NASDAQ:INZY), Atossa Therapeutics (NASDAQ:ATOS) and Aligos Therapeutics (NASDAQ:ALGS).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range0.960 - 10.021 | Open / Close- / - | Float / Outstanding36.568M / 44.074M |
Vol / Avg.2.252K / 998.529K | Mkt Cap94.760M | P/E- | 50d Avg. Price2.030 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float36.568M | EPS-2.400 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.620 | -0.1000 | ||||
REV | 4.270M | 4.024M | -246.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Fortress Biotech (NASDAQ:FBIO), Inozyme Pharma (NASDAQ:INZY), Atossa Therapeutics (NASDAQ:ATOS) and Aligos Therapeutics (NASDAQ:ALGS).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range0.960 - 10.021 | Open / Close- / - | Float / Outstanding36.568M / 44.074M |
Vol / Avg.2.252K / 998.529K | Mkt Cap94.760M | P/E- | 50d Avg. Price2.030 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float36.568M | EPS-2.400 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.620 | -0.1000 | ||||
REV | 4.270M | 4.024M | -246.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Fortress Biotech (NASDAQ:FBIO), Inozyme Pharma (NASDAQ:INZY), Atossa Therapeutics (NASDAQ:ATOS) and Aligos Therapeutics (NASDAQ:ALGS).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.